advertisement
advertisement

This revolutionary vaccine could eradicate the deadly Ebola virus

Merck’s Ervebo reduces fatalities by at least 88% in people exposed to the virus.

This revolutionary vaccine could eradicate the deadly Ebola virus
[Source images: PandaWild/IStock (texture); ~UserGI15632523/iStock (medical vials); valio84sl/iStock (syringes)]
THE WORLD’S 50 MOST INNOVATIVE COMPANIES
18 Merck

After receiving FDA approval for the Ebola vaccine Ervebo in 2019, Merck is poised to eradicate the deadly virus. The process began six years ago, when Merck licensed the treatment from New Link Genetics and set to work developing it and “showing that it was generally safe and effective,” says Roger Perlmutter, president of Merck Research Laboratories. Merck figured out how to scale manufacturing of the inoculation, which consists of a genetically engineered live virus that triggers an immune response, and delivered more than 250,000 doses to the Democratic Republic of Congo (site of the most recent outbreak). It reduced mortality by at least 88% among people exposed to the virus.

advertisement
advertisement
advertisement